NCT02534480View on ClinicalTrials.gov

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

NGP 555

Gamma-secretase modulator for the treatment of Alzheimer's disease

Trial Locations (1)

90630

WCCT, Cypress

Sponsors
All Listed Sponsors
lead

NeuroGenetic Pharmaceuticals Inc

INDUSTRY

NCT02534480 - Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) | Biotech Hunter | Biotech Hunter